Reappraisal of the role of radiation therapy in lymphoma treatment

Lena Specht*

*Corresponding author af dette arbejde
2 Citationer (Scopus)

Abstract

Radiation therapy (RT) for lymphomas has improved dramatically with modern imaging and treatment techniques, encompassing only the necessary volume with minimal doses to normal structures. Prescribed radiation doses are reduced, and fractionation schedules are under revision. With effective systemic treatment only initial macroscopic disease is irradiated. With no or less effective systemic treatment, possible microscopic disease is also included. Risks of long-term side effects of RT have diminished dramatically and should be weighed against risks from more systemic treatment or increased risk of relapse. Lymphoma patients are often elderly, they tolerate modern limited RT very well. Lymphomas refractory to systemic treatments often remain radioresponsive, and brief, mild RT may offer effective palliation. New roles for RT are emerging with immune therapies. RT for "bridging," keeping the lymphoma under control while waiting for immune therapy, is well established. Enhancement of the immune response to lymphomas, so-called "priming," is being intensively researched.

OriginalsprogEngelsk
TidsskriftHematological Oncology
Vol/bind41 Suppl 1
Sider (fra-til)75-81
Antal sider7
ISSN0889-8588
DOI
StatusUdgivet - jun. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Reappraisal of the role of radiation therapy in lymphoma treatment'. Sammen danner de et unikt fingeraftryk.

Citationsformater